BioTrinity 2011: UK Company Showcase - Biotech, Platform Tech and Medtech
BioTrinity 2011 will be a unique opporunity to take in up to 60 corporate/investor presentations from across the major bioclusters of the UK*, the first 34 firms confirmed for the 2011 showcase include: Adaptimmune, Amakem, Aquapharm Discovery, Apitope, Astex, BioOxyDyn, BioVex, BTG plc, Cellzome, Cizzle Biotech, Conformetrix, Convergence Pharma, Creabilis SA, Critical Pharmaceuticals, Cyprotex, Cytox, E-Therapeutics plc, Future Injection, Hypha Discovery, Immunocore, Kymab, MorphoSys AG, OET, Oxford Biomedica plc, PsiOxus, Phylogica, ProCarta BioSystems, Pro-Cure Therapeutics, Protaffin Biotechnologie, Silence Therapeutics plc, Simugen, Spirogen Ltd, Syntaxin, and Vantia Therapeutics.*includes a small number of European firms with facilities in the UK, as well as firms where part or all of the senior management team is based in the UK.The BioTrinity 2010 Company Showcase was a unique opportunity to take in 36 corporate/investor presentations from the best companies from the UK's most successful bioclusters and partner with them. This year we will again feature a mostly hand-selected line-up of the Most Promising Companies over April 13-14th 2010. Day one will feature drug discovery and development as well as platform technologies, and Day Two will feature medtech as well as platform companies. Do contact us soon if you wish to be considered for one of the few remaining presenting slots, since over 80% are already allocated and a number of companies are being considered for what remains. We are also delighted to have accepted our first presentation from the MassBio cluster in Boston, US.
|
|
Tuesday, 13th April 2010 |
|
12.00 |
Day 1 - BioTrinity 2010 Company Showcase (sponsored by Shire): From Concept to Patient - Biotechnology |
 |
12.00 Shire - David Colpman, Shire Pharmaceuticals- Introducing the Company Showcase |
 |
12.10 BioVex - Colin Love, SVP |
 |
12.20 Chroma Therapeutics - Ian Nicholson, CEO |
Refreshments and Networking
12.30 - 13.30 |
Lunch and Exhibition Viewing |
 |
13.30 Summit plc - Steven Lee, CEO |
 |
13.40 Saturn Biosciences - Nigel Courtenay-Luck, Co-Founder & CSO |
 |
13.50 Synairgen Research - Philip Monk, Chief Scientific Officer |
 |
14.00 Syntaxin - Melanie Lee, CEO |
 |
14.10 Aquapharm Biodiscovery - Andrew Mearns Spragg, CEO |
 |
14.20 Hypha Discovery - Liam Evans, CEO |
 |
14.30 Karus Therapeutics - Simon Kerry, CEO |
 |
14.40 CellCentric - David Knowles, CSO |
15.00 - 15.30 |
|
 |
14.50 Pro-Cure Therapeutics - Michael J. Mclean, CEO |
|
15.30 Ixo Limited - Douglas Thomson, CEO |
 |
15.40 Technomark Life Sciences - Allen Hakimi, MD |
 |
15.50 BigDNA - John March, CEO |
|
16.00 Isogenica - Ambili Nair, Business Development |
 |
16.10 Physiomics - Dr Christophe Chassangnole, COO |
 |
16.20 Cyprotex - Dr Anthony D Baxter, CEO |
 |
16.30 Oxford Nanopore - Jim McDonald, Finance Director |
 |
16.40 London Genetics - Dominique Kleyn, CEO |
 |
16.50 Inhibox - Paul Davie, CCO |
17.00 - 18.00 |
Networking Reception Sponsored by Shire Pharmaceuticals in the Exhibition Hall |
19.30 - 22.30 |
Reception and Gala Dinner in the Hennessy Suite, Hampshire Stand |
|
Wednesday, 14th April 2010 |
|
13.30 |
Day 2 - BioTrinity 2010 Company Showcase: From Concept to Patient - MedTech
|
 |
13:30 Glide Pharma -Simon Jones, CFO |
 |
13:40 G-Nostics - Mark Tucker, CEO |
 |
13:50 RepRegen - Ian Brown, CEO |
 |
14:00 Oxford Contrast Molecular Diagnostics - Richard Jones, CEO |
 |
14:10 Vivacta - Neil Butler, CEO |
 |
14:20 Organox - Les Russell, CEO |
 |
14:30 OrthOx - Nick Skaer, CEO |
 |
14:40 Oxford Immunotec -Peter Wrighton-Smith, CEO |
 |
14:50 Glysure -Chris Jones, CEO |
15.00 - 15.30 |
Refreshments and Networking |
15.30 |
Day 2 - BioTrinity 2010 Company Showcase: From Concept to Patient - Biotech continued...
|
 |
15:30 Domainex - Eddy Littler, CEO |
 |
15:40 Advanced Proteome Therapeutics Inc.(MA, USA) - Alexander Krantz, CEO/President |
 |
15:50 Polytherics - Sally Waterman, COO |
 |
16:00 Lipoxen - Scott Maguire, CEO |
 |
16:10 Pharmidex - Gary Manchee, Global Head of Business Development |
 |
16:20 Immune Targeting Systems - Carlton Brown, CEO |
16.30 |
Conference Close Drinks |
